It has been demonstrated that PPAR-γ agonists act as neuroprotective agents against neurodegenerative diseases, such as stroke [48], Alzheimer's [48,50,51] and Parkinson ́s disease [48]. This evidence concerns the gene PPARG and Parkinson disease.